NCT01500226View on ClinicalTrials.gov

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

1,369

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Rolapitant

(4 X 50 mg capsule) 200 mg PO

DRUG

Granisetron

2 mg PO

DRUG

Dexamethasone

20 mg PO

DRUG

Placebo

(4 X 0 mg capsules) 0 mg PO

Trial Locations (1)

02451

TESARO Inc, Waltham

All Listed Sponsors
lead

Tesaro, Inc.

INDUSTRY

NCT01500226 - Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy | Biotech Hunter | Biotech Hunter